Cardiff Oncology (CRDF) Long-Term Debt Repayments (2016 - 2017)
Cardiff Oncology (CRDF) posted Long-Term Debt Repayments of $15.0 million for Q2 2017, up 128.1% sequentially from $6.6 million in Q3 2016, and up 971.26% YoY from $1.4 million in Q2 2016.
Cardiff Oncology (CRDF) Long-Term Debt Repayments (2016 - 2017) Analysis & Trends
Cardiff Oncology has reported Long-Term Debt Repayments for 2 years, with the latest figure at $15.0 million in Q2 2017.
- Quarterly Long-Term Debt Repayments rose 971.26% year-over-year to $15.0 million in Q2 2017, while the trailing twelve-month figure through Sep 2018 was $15.0 million (changed 0.0% YoY) and the FY2017 annual result came in at $15.0 million, up 68.61% from the prior year.
- Long-Term Debt Repayments climbed to $15.0 million in Q2 2017 per CRDF's latest filing, from $6.6 million in the prior quarter.
- Over five years, Long-Term Debt Repayments peaked at $15.0 million in Q2 2017 and troughed at $919864.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -10.01 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 15.00 Mn |
| Jun 30, 2017 | 15.00 Mn |
| Sep 30, 2016 | 6.58 Mn |
| Sep 30, 2016 | 6.58 Mn |
| Jun 30, 2016 | 1.40 Mn |
| Jun 30, 2016 | 1.40 Mn |
| Mar 31, 2016 | 919,864.00 |
| Mar 31, 2016 | 919,864.00 |